IS7599A - Heterósýklískir kínasatálmar - Google Patents

Heterósýklískir kínasatálmar

Info

Publication number
IS7599A
IS7599A IS7599A IS7599A IS7599A IS 7599 A IS7599 A IS 7599A IS 7599 A IS7599 A IS 7599A IS 7599 A IS7599 A IS 7599A IS 7599 A IS7599 A IS 7599A
Authority
IS
Iceland
Prior art keywords
kinase inhibitors
heterocyclic kinase
heterocyclic
inhibitors
kinase
Prior art date
Application number
IS7599A
Other languages
English (en)
Inventor
M. Borzilleri Robert
S. Tokarski John
Bhide Rajeev
Zheng Peter
Qian Ligang
Cai Zhen-Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS7599A publication Critical patent/IS7599A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7599A 2002-06-20 2004-12-15 Heterósýklískir kínasatálmar IS7599A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39081302P 2002-06-20 2002-06-20
PCT/US2003/019243 WO2004001059A2 (en) 2002-06-20 2003-06-18 Heterocyclic inhibitors of kinases

Publications (1)

Publication Number Publication Date
IS7599A true IS7599A (is) 2004-12-15

Family

ID=30000629

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7599A IS7599A (is) 2002-06-20 2004-12-15 Heterósýklískir kínasatálmar

Country Status (14)

Country Link
US (2) US7084160B2 (is)
EP (1) EP1513818B1 (is)
JP (1) JP4477492B2 (is)
AR (1) AR040272A1 (is)
AT (1) ATE455767T1 (is)
AU (1) AU2003251559A1 (is)
DE (1) DE60331061D1 (is)
ES (1) ES2337246T3 (is)
IS (1) IS7599A (is)
NO (1) NO330043B1 (is)
PE (1) PE20040581A1 (is)
PL (1) PL374272A1 (is)
TW (1) TW200401638A (is)
WO (1) WO2004001059A2 (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
NZ537208A (en) * 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1506203T3 (da) * 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
ES2380201T3 (es) 2003-07-11 2012-05-09 Merck Patent Gmbh Derivados de benzimidazol
EP1684750B1 (en) * 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7449167B2 (en) * 2004-07-08 2008-11-11 Air Products And Chemicals, Inc. Catalyst and process for improving the adiabatic steam-reforming of natural gas
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
RU2445308C2 (ru) * 2005-04-04 2012-03-20 Аб Сьянс Замещенные производные оксазола и их применение в качестве ингибиторов тирозинкиназы
WO2006134989A1 (ja) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2007067257A2 (en) 2005-12-02 2007-06-14 Vanderbilt University Broad-emission nanocrystals and methods of making and using same
EP1976885B1 (en) 2005-12-21 2014-12-03 Amgen Research (Munich) GmbH Pharmaceutical antibody compositions with resistance to soluble cea
CN101346361A (zh) * 2005-12-22 2009-01-14 阿斯利康(瑞典)有限公司 化合物
US8383855B2 (en) 2006-02-14 2013-02-26 President And Fellows Of Harvard College Histone deacetylase inhibitors
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
WO2007120669A1 (en) * 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
ATE537450T1 (de) 2006-06-30 2011-12-15 Schering Corp Igfbp2-biomarker
CN101600714B (zh) 2006-11-10 2013-08-21 百时美施贵宝公司 吡咯并吡啶激酶抑制剂
WO2008086128A2 (en) * 2007-01-05 2008-07-17 Bristol-Myers Squibb Company Aminopyrazole kinase inhibitors
ES2606505T3 (es) * 2007-01-12 2017-03-24 Ab Science Tratamiento de combinación de cánceres sólidos con antimetabolitos e inhibidores de tirosina quinasa
KR101660989B1 (ko) 2007-10-01 2016-09-28 아이오니스 파마수티컬즈, 인코포레이티드 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절
WO2009055053A2 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2721156B1 (en) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20170349540A1 (en) * 2014-07-28 2017-12-07 The General Hospital Corporation Histone deacetylase inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN116751195B (zh) * 2023-06-21 2025-03-07 杭州科兴生物化工有限公司 联吡啶类化合物、其可药用的盐以及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ATE288904T1 (de) * 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
PL373371A1 (en) * 2002-04-23 2005-08-22 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
DK1497019T3 (en) * 2002-04-23 2015-08-03 Bristol Myers Squibb Co PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
NO20045220L (no) 2005-01-19
US20060135576A1 (en) 2006-06-22
JP4477492B2 (ja) 2010-06-09
ATE455767T1 (de) 2010-02-15
NO330043B1 (no) 2011-02-07
US7084160B2 (en) 2006-08-01
PE20040581A1 (es) 2004-09-08
ES2337246T3 (es) 2010-04-22
AU2003251559A1 (en) 2004-01-06
JP2005533808A (ja) 2005-11-10
PL374272A1 (en) 2005-10-03
EP1513818A2 (en) 2005-03-16
DE60331061D1 (de) 2010-03-11
AR040272A1 (es) 2005-03-23
AU2003251559A8 (en) 2004-01-06
TW200401638A (en) 2004-02-01
WO2004001059A2 (en) 2003-12-31
EP1513818A4 (en) 2006-10-04
US7547711B2 (en) 2009-06-16
US20040077696A1 (en) 2004-04-22
WO2004001059A3 (en) 2004-03-04
EP1513818B1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
IS7599A (is) Heterósýklískir kínasatálmar
ATE505471T1 (de) Azaindol-kinaseinhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
CY2016042I1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
DK1490355T3 (da) Indolylmaleimidderivater
DK1370553T3 (da) Rho-kinase-inhibitorer
DK1370552T3 (da) Rho-kinase-inhibitorer
PL373649A1 (en) Kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
DK1704145T3 (da) Selektive kinaseinhibitorer
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
EP1558609A4 (en) KINASE INHIBITORS
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
EP1569907A4 (en) NICOTINAMIDE-BASED KINASE HEMMER
ATE433449T1 (de) Kinaseinhibitoren
ATE389658T1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
EP1570847A4 (en) PHOSPHODIESTERASE 10A HEMMER